ddrg/super_eurlex huggingface dataset:
Official Journal of the European Union

Prior notification of a concentration

(Case M.9603 – SNCF MOBILITES / THIF)

(Text with EEA relevance)

(2022/C 93/08)

1. On 21 February 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — SNCF SA (‘SNCF’, France), — THI Factory (‘THIF’, Belgium). SNCF will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole THIF. The concentration is accomplished by way of contract or any other means.

2. The business activities of the undertakings concerned: — SNCF is the incumbent French railway undertaking. Its activities include rail passenger and freight transport, station and infrastructure management and engineering activities. SNCF exercises sole control over Eurostar International Limited, the operator of international high-speed rail services connecting the United Kingdom with France, Belgium and the Netherlands through the Channel Tunnel between the United Kingdom and France, — THIF is a railway undertaking active in the management and operation of international high-speed rail passenger transport services between France, Belgium, the Netherlands and Germany under the name Thalys.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.9603 – SNCF MOBILITES / THIF Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
Non-opposition to a notified concentration

(Case M.10570 – ADVENT / PERMIRA / MCAFEE)

(Text with EEA relevance)

(2022/C 115/03)

On 24 February 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10570. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.10637 – CERTAS / ENGIE SOLUTIONS / SSEC JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 111/03)

1. On 28 February 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Certas Energy France (‘Certas’, France), controlled by DCC plc (‘DCC’, Ireland), — Engie Energies Service - Engie Solutions (‘Engie Solutions’, France), controlled by Engie SA (‘Engie’, France), — SSEC (France). Certas and Engie acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of SSEC. The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned are: — for Certas: operation of service stations in France on the motorway and road network. Its parent company DCC is active globally across four divisions in various industry areas such as technology, healthcare, LPG and retail & oil, — for Engie Solutions: provision of services related to energy management in France. Its parent company Engie is active globally in the provision of gas, electricity and services related to energy management, — for SSEC: a newly established joint venture, which will be active in the installation and operation of electric vehicle charging stations in France.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10637 – CERTAS / ENGIE SOLUTIONS / SSEC JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10360 – ASSICURAZIONI GENERALI / SOCIETÀ CATTOLICA DI ASSICURAZIONE)

(Text with EEA relevance)

(2022/C 129/03)

On 21 October 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10360. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10657 - SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 123/08)

1. On 11 March 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Samsung BioLogics Co. Ltd. (‘Samsung BioLogics’, South Korea), a company controlled by the Samsung Group (South Korea), and — Samsung Bioepis Co. Ltd. (‘Bioepis, South Korea’), a company currently jointly controlled by Biogen Therapeutics Inc. (USA) and Samsung BioLogics. Samsung BioLogics will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Bioepis. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following: — Samsung BioLogics is a company active in the development and manufacturing of biopharmaceutical products worldwide. — Bioepis is a company active in the development and commercialisation of biosimilar medicines.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10657 - SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10644 – TOWERBROOK CAPITAL PARTNERS / NEW MOUNTAIN CAPITAL / CLOUDMED SOLUTIONS / R1 RCM)

(Text with EEA relevance)

(2022/C 145/02)

On 29 March 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10644. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10583 – CPP INVESTMENTS / VOTORANTIM / JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 134/13)

1. On 17 March 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — CPP Investments (Canada), — Votorantim S.A. (‘Votorantim’, Brazil), — the Joint Venture (‘JV’, Brazil). CPP Investments and Votorantim will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the newly-created JV. The concentration is accomplished by way of purchase of shares in a newly created company constituting a joint venture.

2. The business activities of the undertakings concerned: — CPP Investments is an investment management organisation that invests the funds of the Canada Pension Plan Fund, — Votorantim is active in a variety of business segments, including cement and concrete, mining and metallurgy, concentrated orange juice, chemical specialty markets, electric power generation and financial sector.

3. The JV will invest in and/or develop (a) renewable greenfield projects and (b) new renewable energy opportunities, and will be active exclusively in Brazil.

4. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

5. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10583 – CPP INVESTMENTS / VOTORANTIM / JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.10603 – CARLYLE / ALTADIA)

(Text with EEA relevance)

(2022/C 159/01)

On 18 March 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10603. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration

(Case M.10610 – ARCHER DANIELS MIDLAND SINGAPORE / CLYDE INVESTMENTS)

(Text with EEA relevance)

(2022/C 153/05)

On 21 March 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10610. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.10578 – CVC / EKATERRA)

(Text with EEA relevance)

(2022/C 170/06)

CVC acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of ekaterra. The concentration is accomplished by way of purchase of shares.

On 12 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) involving the acquisition of sole control of ekaterra B.V. (‘ekaterra’) by CVC Capital Partners SICAV-FIS S.A. (‘CVC’) within the meaning of Article 3(1)(b) of Council Regulation (EC) No 139/2004.

for ekaterra : ekaterra and its subsidiaries carry out a tea business, consisting of the cultivation, processing and supply of leaf tea, the researching and developing, manufacturing, producing, packaging, packing, marketing, distributing and selling of tea products worldwide (excluding Unilever’s interests in the PepsiLipton joint ventures with Pepsico in relation to ready-to-drink (‘RTD’) tea).

for CVC : CVC manages investment funds and platforms. One of CVC funds’ portfolio companies, Zabka Polska S.A., is active in grocery retail in Poland;

The business activities of the undertakings concerned are:

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10578 – CVC / EKATERRA

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:
Official Journal of the European Union

Prior notification of a concentration

(Case M.10634 – CVC / GAMING1)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 167/07)

1. On 11 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — CVC Capital Partners SICAV-FIS S.A (‘CVC’, Luxembourg), — Certain entities belonging to the Gaming1 Group (the ‘Target’, Belgium). CVC will acquire within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the Target. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned: — CVC: Private equity fund providing investment advice to and managing investments on behalf of investment funds. CVC holds interests in companies in various industries, including chemicals, utilities, manufacturing, retailing and distribution. — The Target: owns land-based casinos, gaming halls and betting agencies in Belgium, France and Switzerland, and is active in the operation of online gambling websites (casinos and sports betting) and mobile applications in Belgium, Malta, Portugal, France, Switzerland, Spain, Serbia, Colombia and the US.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10634 – CVC / GAMING1 Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
Non-opposition to a notified concentration

(Case M.10707 – MACQUARIE / BCI / REDEN HOLDING AND REDEN HOLDING 2020)

(Text with EEA relevance)

(2022/C 189/03)

On 29 April 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10707. EUR-Lex is the online point of access to European Union law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.10643 – ORACLE / CERNER)

(Text with EEA relevance)

(2022/C 179/03)

1. On 22 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Oracle Corporation (‘Oracle’, USA); — Cerner Corporation (‘Cerner’, USA). Oracle will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Cerner. The concentration is accomplished by way of public bid, through a tender offer to purchase all issued and outstanding shares of Cerner.

2. The business activities of the undertakings concerned are the following: — Oracle is active worldwide in the development, production, marketing, and distribution of IT solutions, including enterprise applications and infrastructure software and services. — Cerner is a global supplier of healthcare provider software and services that support the clinical, financial and operational needs of healthcare provider organisations of all sizes, including providing software and services for electronic health records.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.10643 – ORACLE / CERNER Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).